Pharming Group N.V. ADS, each representing 10 ordinary shares
18.63
USD
Patrocinado
+0.74
+4.14%
09 de jan., 15:33 UTC -5
Encerrado
Pós-Mercado
18.45
-0.18
-0.97%
Relatórios de Lucros PHAR
Rácio de surpresa positiva
PHAR separação 20 de 39 últimas estimativas.
51%
Próximo Relatório
Data do Próximo Relatório
11 de mar. de 2026
Estimate forQ4 25(Revenue/ EPS)
$104.74M
/
$0.00
Mudanças implicadas deQ3 25(Revenue/ EPS)
+7.65%
/
-100.00%
Mudanças implicadas deQ4 24(Revenue/ EPS)
+13.02%
/
--
Pharming Group N.V. ADS, each representing 10 ordinary shares earnings per share and revenue
On 06 de nov. de 2025, PHAR reported earnings of 0.01 USD per share (EPS) for Q3 25, beating the estimate of 0.00 USD, resulting in a 1100.00% surprise. Revenue reached 97.30 milhão, compared to an expected 96.23 milhão, with a 1.11% difference. The market reacted with a +11.53% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of 0.00 USD, with revenue projected to reach 104.74 milhão USD, implying an diminuir of -100.00% EPS, and aumentar of 7.65% in Revenue from the last quarter.
FAQ
What were Pharming Group N.V. ADS, each representing 10 ordinary shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Pharming Group N.V. ADS, each representing 10 ordinary shares reported EPS of $0.01, beating estimates by 1100%, and revenue of $97.30M, 1.11% above expectations.
How did the market react to Pharming Group N.V. ADS, each representing 10 ordinary shares's Q3 2025 earnings?
The stock price moved up 11.53%, changed from $13.18 before the earnings release to $14.70 the day after.
When is Pharming Group N.V. ADS, each representing 10 ordinary shares expected to report next?
The next earning report is scheduled for 11 de mar. de 2026.
What are the forecasts for Pharming Group N.V. ADS, each representing 10 ordinary shares's next earnings report?
Based on 6
analistas, Pharming Group N.V. ADS, each representing 10 ordinary shares is expected to report EPS of -- and revenue of $104.74M for Q4 2025.